A Multi-Center Study of Detection of Low Ventricular Ejection Fraction

Cardiac Disease Clinical Trial

Official title:

A Multicenter Study of Detection of Low Ventricular Ejection Fraction (LVEF) ≤ 40% Based on Point-of-Care 12- Lead ECG Data

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04963218
• Other study ID #: 21-003530
• Status: Completed
• Start date: August 30, 2021
• Est. completion date: April 13, 2022

Study information

• Verified date: July 2022
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a multi-site, retrospective study to evaluate the performance of a locked AI-based algorithm for detection of left ventricular systolic dysfunction. A prerequisite for inclusion of subjects from each institution will be the availability of at least one digital 12-lead ECG paired with an echocardiogram with LVEF information within 30 days of the date of the ECG. The AI-ECG LVSD algorithm will be applied on all ECGs and diagnostic performance features for the detection of LVSD will be estimated using the provided paired LVEF value (Low LVEF as the reference label). Performance will also be assessed in subgroups of subjects determined by demographic and clinical factors.

Description:

Following institutional review board approval, 12,000 12-lead ECG's paired with an echocardiogram with LVEF information within 30 days of the date of the ECG will be collected across three enrolled sites. Each site will provide data from up to 4000 enrolled subjects that meet the inclusion criteria. No other demographic characteristics or enrichment will be considered in the selection of subjects in order to best represent the general population for that site. Sites will securely transfer the data to a centralized repository for processing.

Once data is collected, the device will be used to analyze the ECG data for all enrolled subjects without reference or access to the echocardiogram data. The device will display a binary 36 prediction of the likelihood of LVEF less than or equal to 40%. Results will be compared to the echocardiogram reference standard in accordance with the statistical analysis plan.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16000
• Est. completion date: April 13, 2022
• Est. primary completion date: April 13, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Adult subjects with or without known cardiac disease who are either inpatients or outpatients with ECGs and an echocardiogram within 30-days of the ECG date.

Exclusion Criteria:

• No research authorization provided

• An ECG signal shorter than 10 seconds or that is not interpretable

• An echocardiogram is considered technically challenging

• Only qualitative interpretation of left ventricular systolic function available (i.e., "decreased EF") without a numerical value.

• A paced rhythm

Related Conditions & MeSH terms

• Cardiac Disease
• Heart Diseases

Intervention

Diagnostic Test:
• AI Algorithm to detect LVEF in ECG
A clinical decision support software as a medical device that detects whether a patient has LVEF less than or equal to 40% based upon the input of one or more ECG vectors at the point-of-care.

Locations

Country	Name	City	State
United States	Beth Israel Deacon Medical Center	Boston	Massachusetts
United States	Montefiore Medical Center	Bronx	New York
United States	Monument Health	Rapid City	South Dakota
United States	University of Utah	Salt Lake City	Utah

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	Anumana, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Established Diagnostic Performance	Number of participants with presence of EF less than of equal to 40% identified by 12-lead AI ECG algorithm	1 month

External Links

•   Mayo Clinic Clinical Trials